HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy

• Albina Stocker,

  Affiliations Breast-Center Zürich, Zürich, Switzerland, Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zürich, Switzerland

  ⨯
• Marie-Luise Hilbers,

  Affiliation Breast-Center Zürich, Zürich, Switzerland

  ⨯
• Claire Gauthier,

  Affiliation Breast-Center Zürich, Zürich, Switzerland

  ⨯
• Josias Grogg,

  Affiliation Breast-Center Zürich, Zürich, Switzerland

  ⨯
• Gerd A. Kullak-Ublick,

  Affiliation Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zürich, Switzerland

  ⨯
• Burkhardt Seifert,

  Affiliation Department of Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland

  ⨯
• Zsuzsanna Varga,

  Affiliation Institute of Surgical Pathology, University Hospital Zurich, Zürich, Switzerland

  ⨯
• Andreas Trojan

  * E-mail: trojan@1st.ch

  Affiliations Breast-Center Zürich, Zürich, Switzerland, Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zürich, Switzerland

  http://orcid.org/0000-0001-7257-9312

  ⨯